N-甲基-L-丙氨酸盐酸盐 | 65672-32-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丙氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-甲基-L-丙氨酸盐酸盐
• 英文名称: N-methyl-L-alanine hydrochloride
• 英文别名: (S)-2-(Methylamino)propanoic acid hydrochloride；(2S)-2-(methylamino)propanoic acid;hydrochloride
• CAS: 65672-32-4
• 化学式: C₄H₉NO₂*ClH
• mdl: MFCD00754492
• 分子量: 139.582
• InChiKey: QYXBNPBZWXNBGN-DFWYDOINSA-N

物化性质

• 熔点：
  165.5-166.0 °C(Solv: ethanol (64-17-5); ethyl ether (60-29-7))

计算性质

• 辛醇/水分配系数(LogP)：
  -2.62
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Alpha-methyl-l-alanine, HCl
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Alpha-methyl-l-alanine, HCl
CAS number: 65672-32-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C4H9NO2.ClH
Molecular weight: 139.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  氯甲酸-9-芴基甲酯 、 N-甲基-L-丙氨酸盐酸盐 在 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 以81.4%的产率得到FMOC-N-甲基-L-丙氨酸
  参考文献：
  名称：

  [EN] INHIBITORS OF ENCEPHALITIC ALPHAVIRUSES
  [FR] INHIBITEURS D'ALPHAVIRUS ENCÉPHALITIQUES

  摘要：

  公开号：

  WO2021046315A3
• 作为产物：
  描述：

  (S)-3,4-dimethyl-2,2-bis-trifluoromethyl-oxazolidin-5-one 在 盐酸 作用下， 以 异丙醇 为溶剂， 反应 12.0h， 以84%的产率得到N-甲基-L-丙氨酸盐酸盐
  参考文献：
  名称：

  An Efficient Synthesis of N-Methylamino Acids and Some of Their Derivatives

  摘要：

  通过N-氯甲基化和三乙基硅烷/三氟乙酸处理，从六氟丙酮保护的氨基酸出发，通过立体选择性的一锅法步骤，可以高产率地获得N-甲基氨基酸衍生物。

  DOI：

  10.1055/s-1998-1998

文献信息

• Compounds for inhibiting &bgr;-amyloid peptide release and/or its synthesis
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06211235B1

  公开（公告）日：2001-04-03

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis.

  揭示了一种抑制β-淀粉样肽释放和/或其合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还揭示了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物。
• Structure–Activity Relationships (SAR) of [<small>D</small>-Arg<sup>2</sup>]Dermorphin(1—4) Analogues, <i>N<sup>α</sup></i>-Amidino-Tyr-<small>D</small>-Arg-Phe-X
  作者：Tadashi Ogawa、Tetsuhisa Miyamae、Toru Okayama、Masaki Hagiwara、Shinobu Sakurada、Tadanori Morikawa

  DOI：10.1248/cpb.50.771

  日期：——

  preferable for expression of potent analgesic activity, and that the free carboxyl group is superior in its analgesic activity to that of the esterified or amidated carboxy group at the C-terminal. In addition, N-methylation of the amide bond at the 4th position contributed to improved analgesic activity. These results indicated that the strong and long-lasting analgesic effect of ADAMB is expressed by

  在研究口服给药后具有有效止痛作用的化合物的开发过程中，基于Nα-ami基-甲酰胺的结构，有74个C端类似物（Nα-d基-Tyr-D-Arg-Phe-X）。合成了Tyr-D-Arg-Phe-MeβAla-OH（ADAMB）。在皮下和口服给药后，通过鼠尾压力测试评估它们的镇痛活性，并详细检查其结构活性关系（SAR）。结果清楚地表明，对于有效的镇痛活性，优选在X位上​​含有侧链β-氨基酸的化合物，并且，游离羧基的镇痛活性优于酯化或酰胺化的羧基。 C端。此外，在第4位的酰胺键的N-甲基化有助于改善止痛活性。这些结果表明，ADAMB的强而持久的镇痛作用由Nα-酰胺化，酰胺键在第4位的N-甲基化和碳链长度（β-Ala）的协同作用来表达。残基在第4位，这是最合适的结构。
• Methods and compounds for inhibiting &bgr;-amyloid peptide release and/or its synthesis
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US06191166B1

  公开（公告）日：2001-02-20

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  揭示了一种抑制β-淀粉样肽释放和/或合成的化合物，因此在治疗阿尔茨海默病方面具有用途。还揭示了包括抑制β-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05270464A1

  公开（公告）日：1993-12-14

  Novel tetrahydroimidazo[1,4]benzodiazepin-2-(thi)ones possessing anti-HIV-1 activity, compositions containing these compounds as active ingredients, and methods of treating subjects suffering from HIV-1 infection by administering these compounds. The compounds have the basic structure shown in Formula (I): ##STR1##

  小说四氢咪唑[1,4]苯并二氮平-2-(硫)酮具有抗HIV-1活性，含有这些化合物作为活性成分的组合物，以及通过给予这些化合物治疗患有HIV-1感染的受试者的方法。这些化合物具有公式(I)所示的基本结构：##STR1##
• Antiretroviral tetrahydroimidazo[1,4]benzodiazepin-2-(thi)ones
  申请人：Janssen Pharmaceutica N.V.

  公开号：US05371079A1

  公开（公告）日：1994-12-06

  The compounds are of the class of tetrahydroimidazo[1,4]benzodiazepin-2-(thi)ones possessing antiretroviral, especially anti-HIV-1, activity. An illustrative compound is (+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4 ,5,1-jk][1,4]benzodiazepine-2(1H)-thione. These compounds are represented by the formula: ##STR1## The application also discloses compositions containing these compounds as active ingredients and methods of treating subjects suffering from retroviral infections by administering said compounds.

  这些化合物属于四氢咪唑[1,4]苯并二氮平-2-(硫)酮类，具有抗逆转录病毒，尤其是抗HIV-1的活性。一个说明性的化合物是(+)-S-4,5,6,7-四氢-9-氯-5-甲基-6-(3-甲基-2-丁烯基)咪唑[4,5,1-jk][1,4]苯并二氮平-2(1H)-硫酮。这些化合物由以下式子表示：##STR1## 该申请还披露了包含这些化合物作为活性成分的组合物以及通过给予这些化合物治疗患有逆转录病毒感染的受试者的方法。